ME/CFS AUSTRALIA (SA) INC
Registered Charity 698
PO Box 28,
South Australia 5007
North Terrace House,
19 North Terrace,
Hackney, SA, 5069
1300 128 339
Closed over Christmas
(reopened 1 February 2017)
ME/CFS Australia (SA) Inc supports the needs of sufferers of Myalgic Encephalomyelitis, Chronic Fatigue Syndrome and related illnesses. We do this by providing services and information to members.
ME/CFS Australia (SA) Inc aims to keep members informed of various research projects, diets, medications, therapies, news items, etc. All communication, both verbal and written, is merely to disseminate information and not to make recommendations or directives.
Unless otherwise stated, the views expressed on this Web site are not necessarily the official views of the Society or its Committee and are not simply an endorsement of products or services.
Implanted occipital nerve stimulator proves beneficial for Fibromyalgia
Saturday 2 November 2013
Implanted Occipital Nerve Stimulator Proves Beneficial for Fibromyalgia
Occipital Nerve Stimulation in Fibromyalgia: A Double-Blind Placebo-Controlled Pilot Study With a Six-Month Follow-Up.
By Mark Plazier MD, et al.
OBJECTIVE: The goal of this study is to evaluate the effectiveness of occipital nerve stimulation (ONS) as a surgical treatment for fibromyalgia in a placebo-controlled design.
MATERIALS AND METHODS: Eleven patients were selected based on the American College of Rheumatology-90 criteria and implanted with an occipital nerve trial-lead stimulator. Baseline scores for pain, mood, and fatigue were acquired, and patients were randomized in a ten-week double-blinded crossover design with placebo and effective subsensory threshold stimulation (no paresthesias). After finalizing the trial, nine patients were implanted permanently; evaluation was performed prior to surgery and at six months after surgery for pain, fatigue, and mood of the number of trigger points and overall morbidity.
CONCLUSIONS: Our data strongly suggest that ONS is beneficial in the treatment of fibromyalgia. The beneficial effects are stable at six months after permanent implantation. Subsensory threshold stimulation is feasible in designing a placebo-controlled trial.
Source: Neuromodulation, October 7, 2013. By Mark Plazier MD, Ingrid Dekelver MD, Sven Vanneste MSc, MA, PhD, Gaëtane Stassijns MD, PhD, Tomas Menovsky MD, PhD, Mark Thimineur MD, PhD and Dirk De Ridder MD, PhD. Department of Translational Neuroscience, Faculty of Health science and Medicine University Antwerp, Antwerp, Belgium; Department of Neurosurgery, University Hospital Antwerp, Antwerp, Belgium.
The above originally appeared here.
blog comments powered by Disqus